Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical- stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its exploratory maintenance dosing study of VK2735, the company's d ...

Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership role ...

SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at the 44 Annual J.P. Morgan Healthcare Conference. The conference will take place January 12- 15, 2026, in San Francisco, California. Details are as follows: About Viking Therapeutics ...

Group 1: Company Overview - Viking Therapeutics Inc is a healthcare service provider specializing in biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline includes VK2809, VK5211, and VK0214 products, with VK2809 and VK0214 being orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta, and VK5211 being an orally available, non-steroidal selective androgen receptor modulator [10]. Group 2: Options Trading Activity - Significant bullish positioning has been observed among high-rolling investors in Viking Therapeutics, with 13 options trades identified, indicating potential privileged information [1]. - The sentiment among major traders is evenly split, with 46% bullish and 46% bearish. Notably, there was one put option worth $35,245 and 12 call options totaling $547,650 [2]. - The predicted price range for Viking Therapeutics, based on volume and open interest analysis, is between $30.0 and $50.0 during the past quarter [3]. - The average open interest for options of Viking Therapeutics is 2,520.33, with total volume reaching 1,069.00, indicating active trading within the strike price corridor of $30.0 to $50.0 over the last 30 days [4]. Group 3: Options Trading Details - The largest options trades include a bullish call option with a strike price of $30.00, totaling $100.9K, and a neutral call option with a strike price of $37.50, totaling $100.0K. Other notable trades include a bearish call option at a strike price of $35.00 and another bullish call option at a strike price of $40.00 [9]. Group 4: Market Performance - The current trading volume for VKTX is 3,016,844, with the stock price down by 0.16%, reaching $38.49. Current RSI values indicate that the stock is neutral between overbought and oversold [15]. - A market expert has issued a consensus target price of $107.0 for Viking Therapeutics, with a Buy rating maintained by an analyst from Canaccord Genuity [12][13].

Core Insights - Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders [2] - The company will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, in New York City, including a fireside chat on December 2 [1] Company Overview - Viking Therapeutics specializes in first-in-class or best-in-class therapies for metabolic and endocrine disorders, with two programs currently in clinical trials [2] - The company's lead program, VK2735, is a dual agonist targeting GLP-1 and GIP receptors, showing positive safety and clinical benefit in Phase 1 and Phase 2 trials [2] - VK2809, another key program, is an orally available small molecule for treating lipid and metabolic disorders, achieving primary and secondary endpoints in a Phase 2b study for NASH and fibrosis [2] - The company is also developing VK0214 for X-linked adrenoleukodystrophy (X-ALD), which demonstrated safety and significant reductions in VLCFAs in a Phase 1b trial [2]

VK2735 Development Programs - VANQUISH Phase 3 program is underway for VK2735, a GLP-1/GIP dual agonist for obesity[7, 67] - VENTURE Oral Phase 2 obesity study for VK2735 Oral, a GLP-1/GIP dual agonist, successfully achieved its primary endpoint[7, 10] - An Amylin agonist for obesity has an IND planned for 1Q26[7, 8] - VK2809, a selective thyroid receptor-β agonist for MASH, reported successful Phase 2b data in 2Q24[7, 8] - VK0214, a selective thyroid receptor-β agonist for X-ALD, reported successful Phase 1b data in 4Q24[7, 8] VK2735 Oral Phase 1 Study Results - After 28 days of oral dosing, up to 8.2% reduction in body weight was observed[22] - At 100 mg dose, up to approximately 7% placebo-adjusted weight loss was observed[15] - Weight loss effects were largely maintained through Day 57, four weeks from the last study dose[20] VK2735 VENTURE Oral Phase 2a Study Results - Up to 12.2% reduction from baseline in body weight was observed after 13 weeks[29, 32, 48] - A statistically significant difference vs placebo was observed at all time points for doses >15 mg[34] - In an exploratory maintenance cohort, down-titration from 90mg to 30mg produced continued gradual weight loss through Week 13[42] VK2735 Subcutaneous Formulation VENTURE Phase 2 Study Results - Up to 14.7% mean weight loss was observed after 13 weeks of VK2735 treatment[55, 66] - In the MAD study, a dose-dependent improvement in weight loss of up to 7.8% (6% placebo-adjusted) was reported after 28 days in subjects with BMI ≥30[50] Financial Information - As of September 30, 2025, the company had $714.57 million in cash and short-term investments[74] - Cash burn year-to-date as of September 30, 2025, was $188.042 million[74]

Company Overview - Viking Therapeutics is a San Diego-based company focused on metabolic and endocrine disorders with approximately 55 employees [3]. Clinical Programs - The company is developing VK2735, a GLP-1/GIP dual agonist for obesity, which is currently in a Phase III program known as the VANQUISH program [3]. - An oral formulation of VK2735 has recently completed a Phase II study, with data to be discussed in the presentation [3]. - An amylin agonist is approaching the clinic, with an IND filing expected in the first quarter [4]. - Additional programs include VK2809, which has completed a Phase IIb study in MASH, and VK0214, which has gone through a Phase Ib study in X-linked adrenoleukodystrophy; however, these programs are not actively being developed [4].

Viking Therapeutics Conference Call Summary Company Overview - **Company**: Viking Therapeutics (NasdaqCM: VKTX) - **Focus**: Metabolic and endocrine disorders - **Location**: San Diego, California - **Employees**: Approximately 55 Key Programs and Developments - **VK2735**: A GLP-1 GIP dual agonist for obesity - Currently in Phase III program called the VANQUISH program [4][35] - Oral formulation recently completed Phase II study [4][35] - **Amylin Agonist**: Expected to file an IND in the first quarter of 2026 [5][36] - **VK2809**: A thyroid receptor beta agonist that has completed a Phase IIb study in NASH [5] - **VK0214**: Another thyroid receptor beta agonist that has completed a Phase Ib study in X-linked adrenoleukodystrophy [5] Clinical Data and Efficacy - **VK2735 Oral Formulation**: - Phase II study showed up to 12.2% body weight reduction after 13 weeks of dosing [20][29] - Weight loss maintained for four weeks after the last dose [10][20] - Excellent tolerability with most adverse events classified as mild to moderate [21][29] - **VK2735 SubQ Formulation**: - Phase II study showed weight loss of 9% to 15% from baseline after 13 weeks [25][30] - Durable weight loss observed 21 days after the last dose [23][30] - Excellent tolerability with 98% of adverse events classified as mild to moderate [24][30] Pipeline and Future Studies - **VANQUISH Phase III Studies**: - VANQUISH I: Completed enrollment, focusing on obesity [30][35] - VANQUISH II: Expected to complete enrollment in the first quarter of next year [30][35] - **Maintenance Study**: Ongoing with a focus on transitioning from weekly to monthly dosing [33][34] Financial Overview - **Cash Position**: Over $700 million as of the third quarter, expected to fund through the VANQUISH Phase III data readouts [34][35] Additional Insights - The company is prioritizing mid-range doses for the oral formulation based on pharmacokinetics and gastrointestinal tolerability [37] - The potential for transitioning from SubQ to oral dosing to maintain weight loss is being explored [37] This summary encapsulates the key points from the Viking Therapeutics conference call, highlighting the company's focus on metabolic disorders, clinical program advancements, and financial health.

Core Insights - Viking Therapeutics has completed patient enrollment ahead of schedule for its Phase 3 VANQUISH-1 clinical trial of VK2735, indicating strong interest in new obesity treatments [1][3] - The trial enrolled approximately 4,650 adults with obesity or overweight conditions, assessing the efficacy and safety of VK2735 over 78 weeks [2] - Positive results from the Phase 2 VENTURE study of VK2735 showed significant weight reduction and favorable safety profiles [4] Company Overview - Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, with VK2735 being a dual agonist of GLP-1 and GIP receptors [1][6] - The company is also developing VK2809 for lipid and metabolic disorders and VK0214 for X-linked adrenoleukodystrophy [7] Clinical Trials - The Phase 3 VANQUISH-1 study is a randomized, double-blind, placebo-controlled trial with four treatment arms, focusing on weight change from baseline as the primary endpoint [2] - A 52-week extension period is included for participants to continue treatment after the primary dosing period [2] - Concurrently, the Phase 3 VANQUISH-2 study is enrolling patients with type 2 diabetes and obesity, expected to complete enrollment in Q1 2026 [3] Mechanism of Action - VK2735 acts on GLP-1 and GIP receptors, which are known to decrease glucose levels, reduce appetite, and improve insulin sensitivity [5] - The dual agonist approach aims to enhance therapeutic benefits compared to existing treatments [5]

Core Insights - Viking Therapeutics announced new clinical data from the VK2735 obesity program, showing improvements in cardiometabolic parameters after 13 weeks of treatment, including reductions in prediabetes and metabolic syndrome prevalence [1][5]. Clinical Trial Results - In the Phase 2 VENTURE clinical trial, 78% of VK2735-treated patients who were prediabetic at baseline achieved normal glycemic status by Week 13, compared to 29% in the placebo group (p=0.0008) [2]. - Among patients with metabolic syndrome at baseline, 68% of those treated with VK2735 no longer met the criteria for the syndrome at Week 13, versus 38% for placebo (p=0.02) [3]. Weight Loss and Safety - VK2735 treatment resulted in statistically significant mean body weight reductions of up to 14.7% from baseline after 13 weeks, with 88% of VK2735 patients achieving at least 10% weight loss compared to 4% for placebo [6]. - The treatment demonstrated a favorable safety profile, with 92% of treatment-emergent adverse events classified as mild or moderate [7]. Future Studies - Viking is conducting a Phase 3 study (VANQUISH-1) to evaluate VK2735's effects on body weight and other health parameters in patients with obesity or overweight and related comorbidities [5][9].